<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id><journal-title-group><journal-title>Pharmaceuticals</journal-title></journal-title-group><issn pub-type="epub">1424-8247</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7821947</article-id><article-id pub-id-type="pmid">33374928</article-id><article-id pub-id-type="doi">10.3390/ph14010002</article-id><article-id pub-id-type="publisher-id">pharmaceuticals-14-00002</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Inhalation of Essential Oil from Mentha piperita Ameliorates PM10-Exposed Asthma by Targeting IL-6/JAK2/STAT3 Pathway Based on a Network Pharmacological Analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Mi Hye</given-names></name></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Sang Jun</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5308-2386</contrib-id><name><surname>Yang</surname><given-names>Woong Mo</given-names></name><xref rid="c1-pharmaceuticals-14-00002" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-pharmaceuticals-14-00002">Department of Convergence Korean Medical Science, College of Korean Medicine, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Korea; <email>kimmihye526@khu.ac.kr</email> (M.H.K.); <email>everythingisok@khu.ac.kr</email> (S.J.P.)</aff><author-notes><corresp id="c1-pharmaceuticals-14-00002"><label>*</label>Correspondence: <email>wmyang@khu.ac.kr</email>; Tel.: +82-2-961-2209</corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>12</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2021</year></pub-date><volume>14</volume><issue>1</issue><elocation-id>2</elocation-id><history><date date-type="received"><day>10</day><month>11</month><year>2020</year></date><date date-type="accepted"><day>18</day><month>12</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Fine particulate matter (PM) exposure exhibits a crucial risk factor to exacerbate airway epithelial remodeling, fibrosis, and pulmonary destruction in asthma. Based on the use of essential oils from aromatic plants on pain relief and anti-inflammatory properties, we investigated the inhibitory effects of essential oil derived from the Mentha species (MEO) against asthma exposed to PM10. The MEO (0.1 <italic>v</italic>/<italic>v</italic> %) was aerosolized by a nebulizer to ovalbumin and PM10-induced asthmatic mice. Histological changes were confirmed in the lung tissues. To define the mode of action of the MEO on asthma, a protein&#x02013;protein interaction network was constructed using menthol and menthone as the major components of the MEO. Cytokine expression and the JAK2/STAT3 signaling pathway were analyzed in lung epithelial A549 cells co-treated with MEO and PM10. Inhalation of MEO by nebulization inhibited respiratory epithelium hyperplasia, collagen deposition, and goblet cell activation in asthmatic mice. Through a network pharmacological analysis, cytokine&#x02013;cytokine receptor interaction and JAK/STAT was expected to be underlying mechanisms of MEO on asthma. Treatment with MEO significantly reduced the IL-6 levels with a decrease in pro-inflammatory and T helper 2-specific cytokines. PM10-induced phosphorylation of JAK2 and STAT3 was significantly decreased by MEO. Collectively, MEO may have an inhibitory effect on asthma under the condition of PM10 exposure through the IL-6/JAK2/STAT3 signaling pathway.</p></abstract><kwd-group><kwd><italic>Mentha</italic> essential oil</kwd><kwd>peppermint oil</kwd><kwd>asthma</kwd><kwd>particulate matter</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceuticals-14-00002"><title>1. Introduction</title><p>Asthma is one of the major allergic respiratory diseases with various symptoms including wheezing, breathlessness, chest tightness and/or coughing, which are induced by airway hyperresponsiveness and pulmonary inflammation, and remodeling [<xref rid="B1-pharmaceuticals-14-00002" ref-type="bibr">1</xref>]. Fine particulate matter (PM) consisting of solid and liquid particles such as black carbon, metals, nitrate, sulfate, polycyclic aromatic hydrocarbons, and automobile exhaust particles have recently been reported to exacerbate respiratory diseases such as asthma, rhinitis, bronchitis, chronic obstructive pulmonary disease (COPD), and hospital admissions as an allergen and, furthermore, are carcinogenic to humans, especially in the lungs [<xref rid="B2-pharmaceuticals-14-00002" ref-type="bibr">2</xref>]. Pollutants such as respirable particulate matter PM<sub>10</sub>, fine particulate matter PM<sub>2.5</sub>, NO<sub>2</sub>, SO<sub>2</sub>, and O<sub>3</sub>, can possibly invade the airways entering the alveolar tissue, which is an important risk factor in the management of asthmatic patients as it lowers their quality of life [<xref rid="B3-pharmaceuticals-14-00002" ref-type="bibr">3</xref>].</p><p>Diverse potential molecular mechanisms have been suggested to clarify the relationship of air pollution exposure with allergic sensitization and asthma exacerbation such as oxidative stress, DNA damage, micronucleus formation, and stimulation of pro-inflammatory factors. Asthma is generally thought to be T helper (Th)-2 pathway-mediated inflammatory disease, which is also triggered by environmental PM [<xref rid="B4-pharmaceuticals-14-00002" ref-type="bibr">4</xref>]. Glencross et al. have suggested that pro-inflammatory cytokines, especially IL-6, are clinically relevant to particulate in the rodent model and humans [<xref rid="B5-pharmaceuticals-14-00002" ref-type="bibr">5</xref>]. A number of studies showed IL-6 leads to the activation of the Janus kinase (JAK) family, and then mediates the phosphorylation of the major transcriptional factor signal transducer and transcription 3 (STAT3) [<xref rid="B6-pharmaceuticals-14-00002" ref-type="bibr">6</xref>]. The STAT3 transcription factor is proposed to be one of the initial activators of Th2 cell program in allergic lung inflammation [<xref rid="B7-pharmaceuticals-14-00002" ref-type="bibr">7</xref>]. Additional research has reported that atmospheric diesel exhaust particulate exposure induces the activation of STAT3 in primary cultures of human airway epithelial cells [<xref rid="B8-pharmaceuticals-14-00002" ref-type="bibr">8</xref>]. Moreover, there is an investigation to find the effects of PM<sub>2.5</sub> on JAK2/STAT3 signaling pathway in human bronchial epithelial cells [<xref rid="B9-pharmaceuticals-14-00002" ref-type="bibr">9</xref>], giving the possibility of a therapeutic target for asthma by inhibiting the JAK/STAT signaling pathway under an air pollution-exposed condition.</p><p>Inhalation of essential oils from aromatic plants by an aerosol spray, nebulizer, or nasal treatment has been regarded as a health enhancer due to their pain relief, and anti-inflammatory and anti-tumor properties [<xref rid="B10-pharmaceuticals-14-00002" ref-type="bibr">10</xref>]. Genus <italic>Mentha</italic> is known as an aromatic species used for food flavoring and medicinal herbs worldwide, because the leaves, flowers, and stems of this genus have been known to contain terpenes/essential oils [<xref rid="B11-pharmaceuticals-14-00002" ref-type="bibr">11</xref>,<xref rid="B12-pharmaceuticals-14-00002" ref-type="bibr">12</xref>]. Essential oils (EOs) of the <italic>Mentha</italic> species, regarded as peppermint oil, was reported to ameliorate histamine and ovalbumin (OVA)-induced bronchial asthma [<xref rid="B13-pharmaceuticals-14-00002" ref-type="bibr">13</xref>]. Interestingly, healthy adults nebulized with <italic>Mentha</italic> EOs (MEO) for 5 min following 1500 m running tests showed significant improvement in lung function and exercise performance [<xref rid="B14-pharmaceuticals-14-00002" ref-type="bibr">14</xref>]. There is accumulating evidence regarding the use of essential oils against urban air pollution to reduce the risk of respiratory diseases [<xref rid="B15-pharmaceuticals-14-00002" ref-type="bibr">15</xref>].</p><p>In the present study, we conducted a protein&#x02013;protein interaction network (PPIN) analysis, an effective pharmacological approach to predict the mechanism of a drug target. Module (M)-network and gene ontology (GO) analysis could offer the molecular mechanism of the anti-asthmatic action of MEO, which is associated with the JAK/STAT pathway. Then, we verified the inhibitory effects of MEO on allergic asthma under the condition of PM<sub>10</sub> exposure by verifying the inhibition of the JAK2/STAT3 signaling pathway and its series Th2-specific cytokine production in vivo and in vitro levels.</p></sec><sec sec-type="results" id="sec2-pharmaceuticals-14-00002"><title>2. Results</title><sec id="sec2dot1-pharmaceuticals-14-00002"><title>2.1. Construction of Menthol and Menthone Network</title><p>There are 100 co-efficient genes and 86 co-efficient genes for menthol and menthone, respectively through PubChem system. In total, 186 genes were yielded to be the targets of MEO. In the process of Protein&#x02013;Protein Interactions (PPI) construction through Genemania, 186 targets were sorted to 108 targets with the score &#x02265;0.7, and 20 targets were added, which mainly related to the 108 targets. Total 128 targets were used to create the network of menthol and menthone, which are two main components of MEO (<xref ref-type="app" rid="app1-pharmaceuticals-14-00002">Table S1</xref>). With the 128 targets of MEO, we performed a protein interaction network, showing interconnectivity either by reported co-expression, co-localization, physical interactions, shared protein domains, predicted, genetic interactions and pathways. The edges showed different correlations between nodes. Through complex interactions involving co-expression, co-localization, physical interactions, shared protein domains, predicted, genetic interactions and pathways, protein interaction network established a total 128 nodes and 1103 edges (<xref ref-type="fig" rid="pharmaceuticals-14-00002-f001">Figure 1</xref>B). Based on this network, functional modules of menthol and menthone were explored by MCODE. 128 targets of MEO were divided into 7 modules including M1, Mineral absorption; M2, Cytokine&#x02013;cytokine receptor interaction; M3, Retinol metabolism; M4, Other glycan degradation; M5, Legionellosis; M6, Th1, and Th2 cell differentiation; M7, Neuroactive ligand&#x02013;receptor interaction as represented by KEGG pathway 2019 Human (<xref ref-type="fig" rid="pharmaceuticals-14-00002-f001">Figure 1</xref>C). GO term of each module were also sorted by <italic>p</italic> value. The most significant term within a module was selected as the one representing the module (<xref rid="pharmaceuticals-14-00002-t001" ref-type="table">Table 1</xref>). Detailed Node IDs of the biological process according to the functional modules were described in <xref ref-type="app" rid="app1-pharmaceuticals-14-00002">Table S2</xref>.</p></sec><sec id="sec2dot2-pharmaceuticals-14-00002"><title>2.2. Module Selection and Cluster of the Enriched Pathway Analysis Using Predicted Targets of Menthol and Menthone</title><p>Among the modules, M2 is cytokine&#x02013;cytokine receptor interaction, which is closely related to the targets affecting asthma. With 10 targets of M2 including IL2, IL4, IFNA1, IL13, CSF2, IL6, IL5, IL10, CSF1, and GUCA2A, we conducted pathway analysis, which was visualized as bar graph, table and clustergram sorted by <italic>p</italic> value. We found that the first cluster of M2 was cytokine&#x02013;cytokine receptor interaction and the second that was JAK-STAT signaling pathway (<xref ref-type="fig" rid="pharmaceuticals-14-00002-f002">Figure 2</xref>A; <xref rid="pharmaceuticals-14-00002-t002" ref-type="table">Table 2</xref>). For Cytokine&#x02013;cytokine receptor interaction, CSF1, CSF2, IFNA1, IL-10, IL-13, IL-2, IL-4, IL-5, and IL-6 were related. For JAK-STAT signaling pathway, targets for cytokine&#x02013;cytokine receptor interaction except CSF1 were related (<xref ref-type="fig" rid="pharmaceuticals-14-00002-f002">Figure 2</xref>B). For this, we could find that the target of M2 affecting asthma were cytokine activation and JAK-STAT signaling pathway among the targets of MEO.</p></sec><sec id="sec2dot3-pharmaceuticals-14-00002"><title>2.3. Effects of Aerosolized MEO on Histological Changes in PM<sub>10</sub>-Exposed Lung Tissues of Mice</title><p>The thickness of epithelial cells in the lung tissues of the PM<sub>10</sub> group was 2.3 times higher than that of the control (CTR) group. The administration of dexamethasone (DEX) to the PM<sub>10</sub>-challanged mice significantly reduced the thickness of epithelium of lung. Airway wall thickening by PM10 exposure was attenuated by MEO treatment (<xref ref-type="fig" rid="pharmaceuticals-14-00002-f003">Figure 3</xref>A). There were 35.3% and 50.3% decreases in epithelial thickness in DEX and MEO-aerosolized mice, respectively, compared to PM<sub>10</sub>-exposed mice (<xref ref-type="fig" rid="pharmaceuticals-14-00002-f003">Figure 3</xref>D). Collagen deposition was increased in the lungs of the PM<sub>10</sub> group than in the CTR group. Nebulizing with DEX and MEO exhibited reduction of blue-stained collagen area in lung tissues (<xref ref-type="fig" rid="pharmaceuticals-14-00002-f003">Figure 3</xref>B). While DEX treatment showed 64.7% decrease of collagen deposition, treatment of MEO by nebulizing in PM<sub>10</sub>-exposed mice significantly attenuated that by 46.3% (<xref ref-type="fig" rid="pharmaceuticals-14-00002-f003">Figure 3</xref>E). In addition, the number of goblet cells was 5 times elevated in the lungs of the PM<sub>10</sub> group than in the CTR group, which was reduced by administration of DEX. We observed that increased goblet cells were markedly suppressed by MEO aerosolization (<xref ref-type="fig" rid="pharmaceuticals-14-00002-f003">Figure 3</xref>C). The reduction rate of MEO on goblet cells area/ppm was 67.8% (<xref ref-type="fig" rid="pharmaceuticals-14-00002-f003">Figure 3</xref>F).</p></sec><sec id="sec2dot4-pharmaceuticals-14-00002"><title>2.4. Effects of MEO on Inflammatory Cytokines Levels in PM<sub>10</sub>-Sensitized A549 Cells</title><p>PM<sub>10</sub> exposure to A549 lung cancer cells induced elevation of inflammatory cytokines mRNA levels. Sensitization of PM<sub>10</sub> significantly elevated the 4.4-fold level of IL-6 in comparison with the non-treated cells. Increased IL-6 level by PM<sub>10</sub> was significantly decreased by 68.5% in 10<sup>&#x02212;3</sup> /mL (<italic>v</italic>/<italic>v</italic> %) of MEO-treated cells (<xref ref-type="fig" rid="pharmaceuticals-14-00002-f004">Figure 4</xref>A). After PM<sub>10</sub> exposure for 24 h, mRNA expression of the pro-inflammatory cytokines including TNF-&#x003b1; (5.5-fold) and IL-1&#x003b2; (8.8-fold) were increased in A549 lung cancer cells. Treatment of 10<sup>&#x02212;3</sup> /mL (<italic>v</italic>/<italic>v</italic> %) of MEO significantly reduced the expressions of TNF-&#x003b1; and IL-1&#x003b2; by 81.9% and 85.8%, respectively, in PM<sub>10</sub>-exposed cells. Similar effects were shown in the results of IL-5 and IL-8 mRNA expressions. PM<sub>10</sub>-induced increase of IL-5 level was reduced by 10<sup>&#x02212;3</sup> /mL (<italic>v</italic>/<italic>v</italic> %) of MEO treatment. Moreover, there were about 58.9% and 70.4% decreases of IL-8 expressions in MEO 10<sup>&#x02212;4</sup> and 10<sup>&#x02212;3</sup> /mL (<italic>v</italic>/<italic>v</italic> %)-treated cells (<xref ref-type="fig" rid="pharmaceuticals-14-00002-f004">Figure 4</xref>B). In addition, Th2-specific cytokines, IL-4 and IL-13, were elevated 4.4 and 6.1 times by PM<sub>10</sub> sensitization compared to non-treated cells. The mRNA level of IL-4 in MEO 10<sup>&#x02212;4</sup> /mL (<italic>v</italic>/<italic>v</italic> %)-treated cells was lower than only PM<sub>10</sub>-exposed cells. IL-13 expressions were significantly altered by both 10<sup>&#x02212;4</sup> and 10<sup>&#x02212;3</sup> /mL (<italic>v</italic>/<italic>v</italic> %) of MEO-treated cells (<xref ref-type="fig" rid="pharmaceuticals-14-00002-f004">Figure 4</xref>C).</p></sec><sec id="sec2dot5-pharmaceuticals-14-00002"><title>2.5. Effects of MEO on Proliferative MMPs, Especially MMP-2 and MMP-9, Levels in PM<sub>10</sub>-Sensitized A549 Cells</title><p>There were 9.3, 3.5, and 18.2 times increases in MMP-2 and MMP-9 levels in PM<sub>10</sub>-exposed cells. The treatment of 10<sup>&#x02212;5</sup>, 10<sup>&#x02212;4</sup>, and 10<sup>&#x02212;3</sup> /mL (<italic>v</italic>/<italic>v</italic> %) of MEO significantly decreased the MMP-2 mRNA expressions in PM<sub>10</sub>-treated cells by 26.0%, 68.5%, and 86.6%. Also, the production of MMP-9 in MEO-treated cells at the concentrations of 10<sup>&#x02212;4</sup> and 10<sup>&#x02212;3</sup> /mL (<italic>v</italic>/<italic>v</italic> %) was lower than in the PM<sub>10</sub>-treated cells (<xref ref-type="fig" rid="pharmaceuticals-14-00002-f004">Figure 4</xref>D).</p></sec><sec id="sec2dot6-pharmaceuticals-14-00002"><title>2.6. Effects of MEO on JAK/STAT3 Signaling Pathway in PM<sub>10</sub>-Sensitized A549 Cells</title><p>The JAK1 and JAK2 were phosphorylated by stimulating PM<sub>10</sub> in A549 cells. Increase rates of JAK1 and JAK2 by PM<sub>10</sub> exposure were 2.0 and 4.4 times compared to non-treated cells. The phosphorylation of JAK2 was significantly decreased in the 10<sup>&#x02212;</sup><sup>5</sup>, 10<sup>&#x02212;4</sup> and 10<sup>&#x02212;3</sup> /mL (<italic>v</italic>/<italic>v</italic> %) of MEO-treated cells by 34.0%, 37.7% and 76.4%, respectively, compared to the only PM<sub>10</sub>-treated cells. However, the phosphorylated JAK1 was not altered by MEO treatment at all concentrations compared to PM<sub>10</sub>-treated cells (<xref ref-type="fig" rid="pharmaceuticals-14-00002-f005">Figure 5</xref>A). Additionally, PM<sub>10</sub> incubation resulted in STAT3 phosphorylation by 1.4 times compared to non-treated cells. The treatment of MEO in the 10<sup>&#x02212;4</sup> and 10<sup>&#x02212;3</sup> /mL (<italic>v</italic>/<italic>v</italic> %)-treated cells markedly the phosphorylated levels of STAT3 by 29.9% and 37.7%, respectively (<xref ref-type="fig" rid="pharmaceuticals-14-00002-f005">Figure 5</xref>B).</p></sec><sec id="sec2dot7-pharmaceuticals-14-00002"><title>2.7. Effects of MEO on NF-&#x003ba;B Translocation into Nucleus in PM<sub>10</sub>-Sensitized A549 Cells</title><p>PM<sub>10</sub>-treated A549 cells exhibited the increase of NF-&#x003ba;B levels in nucleus as well as phosphorylation of I&#x003ba;B-&#x003b1; in cytosol compared to non-treated cells. Increase rates of nucleic NF-&#x003ba;B and phosphorylated I&#x003ba;B-&#x003b1; compared with non-treated cells were 1.8 and 3.0 times. Whereas the expression of NF-&#x003ba;B in cytosol was markedly decreased under exposure of PM<sub>10</sub> by about 70%. Treatment with 10<sup>&#x02212;3</sup> /mL (<italic>v</italic>/<italic>v</italic> %) of MEO significantly down-regulated the NF-&#x003ba;B levels by 41.1% in nucleus, while up-regulated that by 94.4% in cytoplasm. In addition, the phosphorylated I&#x003ba;B-&#x003b1; in cytosol in the MEO-treated cells was 34.4% lower than the only PM<sub>10</sub>-treated cells (<xref ref-type="fig" rid="pharmaceuticals-14-00002-f006">Figure 6</xref>).</p></sec></sec><sec sec-type="discussion" id="sec3-pharmaceuticals-14-00002"><title>3. Discussion</title><p>Airway inflammation and remodeling are major features of respiratory diseases in response to air pollution [<xref rid="B16-pharmaceuticals-14-00002" ref-type="bibr">16</xref>]. A number of studies have reported that environmental pollutants negatively cause abnormalities in the respiratory system such as asthma, chronic obstructive pulmonary disease, and lung cancer, because the toxicity of air pollutants inhalation influences the pulmonary epithelium, which has a crucial role in the homeostasis of the lungs [<xref rid="B17-pharmaceuticals-14-00002" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceuticals-14-00002" ref-type="bibr">18</xref>]. Additionally, it is well known that air pollutants exacerbate the damage of pulmonary epithelial cells, leading to airway epithelial remodeling, fibrosis, malignant transformation and pulmonary destruction in asthma [<xref rid="B19-pharmaceuticals-14-00002" ref-type="bibr">19</xref>]. Exposure to PM<sub>10</sub> induced the airway epithelium of the lung tissues to become thicker than normal epithelial cells. In addition, Masson&#x02019;s trichrome-stained collagen deposition indicated by blue intensity occurred in the PM<sub>10</sub>-affected fibrosis of the lung. Aerosolization of MEO through the nebulizer significantly decreased the thickness of the pulmonary epithelium, and the accumulation of airway collagen in the OVA and PM<sub>10</sub>-exposed lung tissues. Furthermore, there is a significant correlation between exposure to air pollution and the proportion of goblet cells [<xref rid="B20-pharmaceuticals-14-00002" ref-type="bibr">20</xref>]. Quantification of functional changes in the airway collagen content and goblet cell population as confirmed by airway reactivity to PM challenge showed MEO may contribute to the homeostasis of the lungs, implicating the potential of MEO inhalation as a therapeutic for PM<sub>10</sub>-affected asthma.</p><p>To clarify the underlying mechanism of MEO on epithelial remodeling and collagen deposition in asthma, a PPI obtained from menthol and menthone as the main components of MEO was constructed based on a network pharmacological analysis. The pathway analysis of the PPI network of MEO revealed that cytokine&#x02013;cytokine receptor interactions and the JAK-STAT signaling pathway were expected to be related to the improvement of asthma by MEO inhalation. Asthma is a typical disease associated with the immune responses of Th2 cells. The production of inflammatory cytokines and mediators at the early stage triggers allergic sensitization, recruitment of eosinophils and neutrophils, and augmented Th2-specific cytokines release. Especially, IL-6-mediated JAK/STAT3 signaling has been proven to play crucial roles in the airway remodeling of asthma [<xref rid="B21-pharmaceuticals-14-00002" ref-type="bibr">21</xref>,<xref rid="B22-pharmaceuticals-14-00002" ref-type="bibr">22</xref>]. Release of IL-6 leads to hyperactivation of JAK/STAT3 by phosphorylation [<xref rid="B23-pharmaceuticals-14-00002" ref-type="bibr">23</xref>]. Growing evidence has shown that ambient PM exposure can trigger lung epithelial remodeling by invading the smallest airways [<xref rid="B24-pharmaceuticals-14-00002" ref-type="bibr">24</xref>,<xref rid="B25-pharmaceuticals-14-00002" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceuticals-14-00002" ref-type="bibr">26</xref>]. Based on the result from the network pharmacological analysis using menthol and menthone of peppermint oil, the roles of IL-6 pro-inflammatory cytokines and JAK/STAT3 activation were explored in the present study. In this study, A549 lung carcinoma cells exposed to PM<sub>10</sub> showed increases of IL-6 and phosphorylation of JAK1/JAK2/STAT3 signaling molecules. MEO treatment of PM<sub>10</sub>-exposed lung epithelial cells significantly inhibited the expressions of IL-6. In addition, the phosphorylated STAT3 levels mediated by PM<sub>10</sub> were markedly decreased in the MEO-treated cells. STAT3 is phosphorylated by JAK family, including JAK1, JAK2, and tyrosine kinases 2 [<xref rid="B27-pharmaceuticals-14-00002" ref-type="bibr">27</xref>]. To verify upstream kinases that are responsible for phosphorylation of STAT3, we analyzed the both JAK1 and JAK2 protein expressions in PM<sub>10</sub>-treated cells. The present study found that MEO treatment affected the phosphorylation of JAK2, rather than phosphorylation of JAK1. Taken together, those results suggest that MEO could inhibit the IL-6-mediated JAK2/STAT3 signaling pathway in PM<sub>10</sub>-induced airway remodeling.</p><p>Th2 cells are known to be major orchestrators in pathogenesis of asthma [<xref rid="B28-pharmaceuticals-14-00002" ref-type="bibr">28</xref>]. The role of STAT3 is well known as an epithelial regulator of the allergic response via recruitment of Th2-specific cytokines [<xref rid="B29-pharmaceuticals-14-00002" ref-type="bibr">29</xref>]. It has been demonstrated that the inflammatory cytokines IL-5 and IL-8 are released in A549 human lung cells after treatment with PM<sub>10</sub> [<xref rid="B30-pharmaceuticals-14-00002" ref-type="bibr">30</xref>]. Furthermore, Th2-specific IL-4 and IL-13 cytokines were produced by bronchial epithelial cells via STAT3-dependent allergic inflammation in asthma [<xref rid="B31-pharmaceuticals-14-00002" ref-type="bibr">31</xref>]. Those inflammatory cytokines have been importantly related to the development of asthma to up-regulate the STAT3 signals [<xref rid="B32-pharmaceuticals-14-00002" ref-type="bibr">32</xref>]. We observed the inhibition of pro-inflammatory TNF-&#x003b1;, IL-1&#x003b2;, IL-5, and IL-8 cytokines in A549 cells treated with MEO and PM<sub>10</sub> together compared with PM<sub>10</sub> only treated cells. Th2 cell-mediated IL-4 and IL-13 expressions were also reduced after the treatment with MEO and PM<sub>10</sub>. Moreover, MMP-2 and MMP-9 activities have been found to participate in the progression of asthma and especially shown to be involved in matrix remodeling and inflammation [<xref rid="B33-pharmaceuticals-14-00002" ref-type="bibr">33</xref>]. Based on the previous reports regarding the role of air pollutants on the MMP activity in pulmonary diseases, we investigated the MMP-2 and MMP-9 expressions in PM<sub>10</sub>-exposed A549 lung cancer cells. The MEO treatment significantly alleviated the PM<sub>10</sub>-induced expressions of MMP-2 and MMP-9 in the A549 cells. Taken together, MEO appears to be effective in regulating the PM-associated airway remodeling by its inhibitory activity on IL-6/JAK2/STAT3-mediated cytokine production.</p><p>Several cellular mechanisms, including STAT3, are involved in the pathogenesis of PM-exacerbated respiratory diseases. The NF-&#x003ba;B pathway can enhance tumor development and maintain the production of tumor cells [<xref rid="B34-pharmaceuticals-14-00002" ref-type="bibr">34</xref>]. It has been shown that PM treatment of A549 lung cancer cells resulted in the translocation of NF-&#x003ba;B into the nucleus, while I&#x003ba;B-&#x003b1; is phosphorylated, leading to the inactivation of the NF-&#x003ba;B-I&#x003ba;B-&#x003b1; complex. In addition, the activation of STAT3 mediated by IL-6 can bind to the NF-&#x003ba;B p65 subunit, leading to its activation [<xref rid="B35-pharmaceuticals-14-00002" ref-type="bibr">35</xref>]. In the present study, cells exposed to PM<sub>10</sub> and MEO showed inactivation of the NF-&#x003ba;B-I&#x003ba;B-&#x003b1; complex. MEO regulated the translocation of NF-&#x003ba;B into the nucleus by reducing the phosphorylation of I&#x003ba;B-&#x003b1; simultaneously.</p><p>Given that inflammation and the JAK/STAT3 signaling pathway are potential mechanisms associated with PM<sub>10</sub>, we hypothesized that inhalation of the essential oil derived from the <italic>Mentha</italic> genus, peppermint oil, could inhibit the epithelial remodeling and inflammation in asthma via regulation of IL-6/JAK2/STAT3 signaling pathway according to the network pharmacological analysis. Our results found that PM<sub>10</sub>-induced IL-6 production and JAK2/STAT3 phosphorylation were declined by the MEO treatment, accompanying a decrease in inflammatory responses including cytokines, MMP activation and NF-&#x003ba;B translocation (<xref ref-type="fig" rid="pharmaceuticals-14-00002-f007">Figure 7</xref>). Consequently, aerosolization of peppermint oil by a nebulizer markedly ameliorated the airway epithelium damage against PM<sub>10</sub> such as epithelial remodeling, collagen deposition, and goblet cell hyperactivation in asthma. These findings provide a potential property of MEO for the respiratory system in response to air pollution exposure. Peppermint oil would help to alleviate asthma by inhibiting the IL-6/JAK2/STAT3 pathway.</p></sec><sec id="sec4-pharmaceuticals-14-00002"><title>4. Materials and Methods</title><sec id="sec4dot1-pharmaceuticals-14-00002"><title>4.1. Network Construction</title><p>Two main components of MEO, menthol and menthone, were candidate compounds of peppermint oil for network construction [<xref rid="B36-pharmaceuticals-14-00002" ref-type="bibr">36</xref>]. Information and target of the menthol (PubChem ID: 1254) and menthone (PubChem ID: 26447) were extracted from PubChem (<uri xlink:href="https://pubchem.ncbi.nlm.nih.gov/">https://pubchem.ncbi.nlm.nih.gov/</uri>) and summed (<xref ref-type="fig" rid="pharmaceuticals-14-00002-f001">Figure 1</xref>A). Using GeneMania, we sorted the targets and create PPI. The condition for sorting targets was the score &#x02265;0.7, which means high confidence [<xref rid="B37-pharmaceuticals-14-00002" ref-type="bibr">37</xref>]. Then, PPIN was constructed with the targets sorted by GeneMania using a Cytoscape software according to the previous report [<xref rid="B38-pharmaceuticals-14-00002" ref-type="bibr">38</xref>].</p></sec><sec id="sec4dot2-pharmaceuticals-14-00002"><title>4.2. Pathway Analysis and Module Analysis</title><p>Based on the protein network constructed above, gene set enrichment analysis (GSEA) based on KEGG pathway 2019 Human (<uri xlink:href="https://www.kegg.jp/">https://www.kegg.jp/</uri>) was conducted using Enrichr (<uri xlink:href="https://amp.pharm.mssm.edu/Enrichr/">https://amp.pharm.mssm.edu/Enrichr/</uri>). The pathways were sorted by <italic>p</italic> value, which is the <italic>p</italic> value computed using Fisher&#x02019;s exact test to assess the deviation from the expected rank. To see the detailed network of MEO, we performed a module division and analysis using a Molecular Complex Detection (MCODE) in Cytoscape. The condition for division was node score cut off = 0.2, K-core = 2, and degree cutoff = 2. For the modules of MEO, after selecting module (M) 2, we conducted pathway analysis based on KEGG pathway 2019 Human, and also GO term analysis based on GO Biological Process 2018 (<uri xlink:href="http://geneontology.org/">http://geneontology.org/</uri>) in Enrichr. The KEGG pathway and GO term of each module were sorted by <italic>p</italic> value. We excluded <italic>p</italic> value &#x0003e; 0.05 of KEGG pathway and GO term in system and selected one representing term, which had lowest <italic>p</italic> value in each module. Clustergram of pathways and genes was also constructed in Enrichr.</p></sec><sec id="sec4dot3-pharmaceuticals-14-00002"><title>4.3. Peppermint Oil Extraction from Mentha Piperita Linn</title><p>The leaves of <italic>Mentha piperita</italic> Linn. was purchased from Dong-Yang Herb Inc. (Seoul, Korea). The essential oil extraction was proceeded by hydrodistillation method. Briefly, 100 g of <italic>M. piperita</italic> Linn. was placed within a 1 L round-bottom flask with clevenger apparatus. Steam distillation was performed for 6 h at 100 &#x000b0;C and the obtained volatile oil was 1.6 mL (yield of MEO: 1.60%). A voucher specimen (01-02-01-KR-191217) was deposited at Department of Convergence Korean Medical Science, College of Korean Medicine, Kyung Hee University, Seoul, Korea.</p></sec><sec id="sec4dot4-pharmaceuticals-14-00002"><title>4.4. PM<sub>10</sub>-Exposed Animal Treatment</title><p>The experimental protocols were approved by the Institutional Animal Ethics Committee of Kyung Hee University in Korea (KHUASP(SE)-19-098; Seoul, Korea). Female BALB/c mice aged 5 weeks were obtained from Raonbio Inc. (Yongin, Korea) and housed in plastic cages. All mice were kept under a 12 h light/dark cycle at a temperature of 22 &#x000b1; 2 &#x000b0;C and relative humidity of 55 &#x000b1; 10%. After 1 week of accumulation, mice were randomly subjected into 4 groups (<italic>n</italic> = 7); (1) CTR, normal mice, (2) PM<sub>10</sub>, PM<sub>10</sub> and ovalbumin (OVA)-exposed mice treated with vehicle, (3) PM<sub>10</sub> + DEX, PM<sub>10</sub> and OVA-exposed mice treated with DEX as positive control and (4) PM<sub>10</sub> + MEO, PM<sub>10</sub> and OVA-exposed mice treated with MEO. All mice except CTR group were intraperitoneally injected 10 &#x003bc;g OVA emulsified in 500 &#x003bc;g aluminum hydroxide with a total volume of 0.1 mL saline on day 0, 7, and 15. Following the sensitization, mice were challenged with 1 mg OVA and 100 &#x003bc;g PM<sub>10</sub> supplemented in 50 &#x003bc;L saline by intranasal instillation on day 21, 22. To inhale saline, DEX and MEO, we self-manufactured exposure chamber with nebulizer (Philips, Amsterdam, Netherlands). The tips of 50 mL conical tubes were cut into 1 cm and sealed with plastic round container. The container was connected to nebulizer, and then mice were loaded into the conical tubes to expose the vapor [<xref rid="B39-pharmaceuticals-14-00002" ref-type="bibr">39</xref>]. Sprayed amount of nebulizer was 1 mL/min. CTR and PM<sub>10</sub> groups were received saline. DEX at a concentration of 2 mg/kg (calculated to 0.06% in saline) was treated to mice to PM<sub>10</sub> + DEX group by nebulizer. The mice of PM<sub>10</sub> + MEO group were nebulized with 0.1 <italic>v</italic>/<italic>v</italic> % of MEO in self-manufactured exposure chamber. All treatments were performed for 5 min once a day from day 0 to day 23. At the end of the experiment on day 24, mice were sacrificed.</p></sec><sec id="sec4dot5-pharmaceuticals-14-00002"><title>4.5. Histology</title><p>Lung tissues were fixed in 10% neutralized formalin for 24 h and then dehydrated with ethanol and xylene. After embedding in paraffin, specimens were cut into 5 &#x003bc;m thickness. Each slide was stained using Hematoxylin and Eosin solution, Masson&#x02019;s trichrome staining solution and Periodic acid&#x02013;Schiff (PAS) solution, respectively, according to the manufacture&#x02019;s instruction. Histopathological changes were examined using the Leica Application Suite (LAS; Leica Microsystems, Buffalo Grove, IL, USA). The thickness of epithelium and blue-stained collagen deposition was determined using an Image J computerized densitometry system. The number of goblet cells was measured in the entire fields of slide for each sample (<italic>n</italic> = 7).</p></sec><sec id="sec4dot6-pharmaceuticals-14-00002"><title>4.6. PM<sub>10</sub>-Exposed in Vitro Experiments</title><p>The human pulmonary epithelial carcinoma-derived A549 lung epithelial cell line was kindly provided from Prof. Ahn, Kyung Hee University, Seoul, Republic of Korea. The cells were cultured in Dulbecco&#x02032;s Modified Eagle&#x02032;s Medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin at 37 &#x000b0;C and 5% CO<sub>2</sub> atmosphere. A549 cells were seeded in 6 well plates at 7.5 &#x000d7; 10<sup>5</sup> cells/well until 80% confluence. Then, cells were exposed to 100 &#x003bc;g/mL of PM<sub>10</sub> in the presence of 10<sup>&#x02212;5</sup>, 10<sup>&#x02212;4</sup> and 10<sup>&#x02212;3</sup> /mL (<italic>v</italic>/<italic>v</italic> %) of MEO for 24 h. Urban dust SRM 1649b, as known as PM<sub>10</sub>, was provided from the National Institute of Standards and Technology (Gaithersburg, MD, USA).</p></sec><sec id="sec4dot7-pharmaceuticals-14-00002"><title>4.7. Western Blot Analysis</title><p>After treatment with PM<sub>10</sub> and MEO, A549 cells were cultured and lysed with radioimmunoprecipitation assay buffer (50 mM Tris&#x02013;HCl (pH 7.4), 1% Nonidet P-40, 0.5% sodium deoxycholate, 150 mM NaCl) supplemented with a protease inhibitor (Roche, Hoffmann, Valdese, NC, USA). The quantified 10 &#x003bc;g of protein by Bradford method was separated by sodium dodecyl sulfate&#x02013;polyacrylamide gel electrophoresis. Then, separated proteins were transferred onto a polyvinylidene difluoride membrane. 3% bovine serum albumin in Tris-Buffered Saline with 0.1% Tween 20 was incubated in membrane to reduce the non-specific antibody binding. Membranes were incubated overnight with primary antibodies (Cell signaling, Beverly, MA, USA) at 4 &#x000b0;C and continued to incubate with horseradish peroxidase-conjugated secondary antibodies (Cell signaling). Signals were detected with an enhanced chemiluminescence detection system (Amersham Pharmacia Biotech, Uppsala, Sweden). Relative band densities were determined using an Image J computerized densitometry system. The experiments were carried out in triplicate measurements.</p></sec><sec id="sec4dot8-pharmaceuticals-14-00002"><title>4.8. RNA Extraction and RT-PCR</title><p>RNA from A549 cells was extracted using the TRIZOL reagent (Invitrogen Corp., Carlsbad, CA, USA) according to the manufacturer guidelines. 1 &#x003bc;g of RNA was synthesized into cDNA with Maxime RT premix (Invitrogen Corp.) at 45 &#x000b0;C for 60 min and then at 95 &#x000b0;C for 5 min. Then, analysis of gene expression was performed in triplicates using a Maxime PCR premix kit (Invitrogen Corp.). Electrophoresed PCR products were visualized under UV light after ethidium bromide staining. The relative expression levels of target genes were normalized using GAPDH as an internal control. Relative band densities were determined using an Image J computerized densitometry system.</p></sec><sec id="sec4dot9-pharmaceuticals-14-00002"><title>4.9. Statistical Analysis</title><p>Significance was determined by one-way analysis of variance (ANOVA) and Tukey&#x02019;s multiple comparison tests. In all analyses, <italic>p</italic> &#x0003c; 0.05 was taken to indicate statistical significance.</p></sec></sec></body><back><ack><title>Acknowledgments</title><p>We would like to thank Ahn, Kyung Hee University, Seoul, Korea for his materials support, the human pulmonary epithelial carcinoma-derived A549 lung epithelial cell line, which has been a crucial part of our research.</p></ack><fn-group><fn><p><bold>Publisher&#x02019;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><app-group><app id="app1-pharmaceuticals-14-00002"><title>Supplementary Materials</title><p>The following are available online at <uri xlink:href="https://www.mdpi.com/1424-8247/14/1/2/s1">https://www.mdpi.com/1424-8247/14/1/2/s1</uri>. Table S1: Total target genes of menthol and menthone, major compounds of <italic>Mentha piperita</italic>., Table S2: Detailed information of Modules with Node IDs.</p><supplementary-material content-type="local-data" id="pharmaceuticals-14-00002-s001"><media xlink:href="pharmaceuticals-14-00002-s001.zip"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, M.H.K., S.J.P. and W.M.Y.; methodology, M.H.K., S.J.P. and W.M.Y.; software, S.J.P.; validation, M.H.K.; formal analysis, M.H.K.; investigation, M.H.K., S.J.P.; resources, W.M.Y.; data curation, W.M.Y.; writing&#x02014;original draft preparation, M.H.K. and S.J.P.; writing&#x02014;review and editing, M.H.K. and W.M.Y.; visualization, M.H.K.; supervision, W.M.Y.; project administration, W.M.Y.; funding acquisition, W.M.Y. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This research was funded by a National Research Foundation of Korea Grant funded by the Korean government, grant number (NRF-2019R1I1A2A01063598) and a grant from Kyung Hee University, in 2018 (grant number: KHU-20181048).</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted according to the Institutional Animal Ethics Committee of Kyung Hee University in Korea (KHUASP(SE)-19-098; Seoul, Korea).</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data presented in this study are available on request from the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest. </p></notes><ref-list><title>References</title><ref id="B1-pharmaceuticals-14-00002"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quirt</surname><given-names>J.</given-names></name><name><surname>Hildebrand</surname><given-names>K.J.</given-names></name><name><surname>Mazza</surname><given-names>J.</given-names></name><name><surname>Noya</surname><given-names>F.</given-names></name><name><surname>Kim</surname><given-names>H.</given-names></name></person-group><article-title>Asthma</article-title><source>Allergy Asthma Clin. Immunol.</source><year>2018</year><volume>14</volume><fpage>50</fpage><pub-id pub-id-type="doi">10.1186/s13223-018-0279-0</pub-id><pub-id pub-id-type="pmid">30275843</pub-id></element-citation></ref><ref id="B2-pharmaceuticals-14-00002"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jo</surname><given-names>E.-J.</given-names></name><name><surname>Lee</surname><given-names>W.-S.</given-names></name><name><surname>Jo</surname><given-names>H.-Y.</given-names></name><name><surname>Kim</surname><given-names>C.-H.</given-names></name><name><surname>Eom</surname><given-names>J.-S.</given-names></name><name><surname>Mok</surname><given-names>J.-H.</given-names></name><name><surname>Kim</surname><given-names>M.-H.</given-names></name><name><surname>Lee</surname><given-names>K.</given-names></name><name><surname>Kim</surname><given-names>K.-U.</given-names></name><name><surname>Lee</surname><given-names>M.-K.</given-names></name><etal/></person-group><article-title>Effects of particulate matter on respiratory disease and the impact of meteorological factors in Busan, Korea</article-title><source>Respir. Med.</source><year>2017</year><volume>124</volume><fpage>79</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2017.02.010</pub-id><pub-id pub-id-type="pmid">28284326</pub-id></element-citation></ref><ref id="B3-pharmaceuticals-14-00002"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loomis</surname><given-names>D.</given-names></name><name><surname>Grosse</surname><given-names>Y.</given-names></name><name><surname>Lauby-Secretan</surname><given-names>B.</given-names></name><name><surname>El Ghissassi</surname><given-names>F.</given-names></name><name><surname>Bouvard</surname><given-names>V.</given-names></name><name><surname>Benbrahim-Tallaa</surname><given-names>L.</given-names></name><name><surname>Guha</surname><given-names>N.</given-names></name><name><surname>Baan</surname><given-names>R.</given-names></name><name><surname>Mattock</surname><given-names>H.</given-names></name><name><surname>Straif</surname><given-names>K.</given-names></name></person-group><article-title>The carcinogenicity of outdoor air pollution</article-title><source>Lancet Oncol.</source><year>2013</year><volume>14</volume><fpage>1262</fpage><lpage>1263</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(13)70487-X</pub-id><pub-id pub-id-type="pmid">25035875</pub-id></element-citation></ref><ref id="B4-pharmaceuticals-14-00002"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michael Guarnieri</surname><given-names>J.R.B.</given-names></name></person-group><article-title>Outdoor air pollution and asthma</article-title><source>Food Chem. Toxicol.</source><year>1996</year><volume>34</volume><fpage>318</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">8621116</pub-id></element-citation></ref><ref id="B5-pharmaceuticals-14-00002"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glencross</surname><given-names>D.A.</given-names></name><name><surname>Ho</surname><given-names>T.-R.</given-names></name><name><surname>Cami&#x000f1;a</surname><given-names>N.</given-names></name><name><surname>Hawrylowicz</surname><given-names>C.M.</given-names></name><name><surname>Pfeffer</surname><given-names>P.E.</given-names></name></person-group><article-title>Air pollution and its effects on the immune system</article-title><source>Free Radic. Biol. Med.</source><year>2020</year><volume>151</volume><fpage>56</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2020.01.179</pub-id><?supplied-pmid 32007522?><pub-id pub-id-type="pmid">32007522</pub-id></element-citation></ref><ref id="B6-pharmaceuticals-14-00002"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rincon</surname><given-names>M.</given-names></name><name><surname>Irvin</surname><given-names>C.G.</given-names></name></person-group><article-title>Role of IL-6 in Asthma and Other Inflammatory Pulmonary Diseases</article-title><source>Int. J. Biol. Sci.</source><year>2012</year><volume>8</volume><fpage>1281</fpage><lpage>1290</lpage><pub-id pub-id-type="doi">10.7150/ijbs.4874</pub-id><?supplied-pmid 23136556?><pub-id pub-id-type="pmid">23136556</pub-id></element-citation></ref><ref id="B7-pharmaceuticals-14-00002"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>H.</given-names></name><name><surname>Cho</surname><given-names>M.</given-names></name><name><surname>Choi</surname><given-names>G.</given-names></name><name><surname>Na</surname><given-names>H.</given-names></name><name><surname>Chung</surname><given-names>Y.</given-names></name></person-group><article-title>Dynamic control of Th2 cell responses by STAT3 during allergic lung inflammation in mice</article-title><source>Int. Immunopharmacol.</source><year>2015</year><volume>28</volume><fpage>846</fpage><lpage>853</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2015.03.051</pub-id><?supplied-pmid 25871878?><pub-id pub-id-type="pmid">25871878</pub-id></element-citation></ref><ref id="B8-pharmaceuticals-14-00002"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>N.</given-names></name><name><surname>Tal</surname><given-names>T.</given-names></name><name><surname>Graves</surname><given-names>L.M.</given-names></name><name><surname>Gilmour</surname><given-names>I.</given-names></name><name><surname>Linak</surname><given-names>W.</given-names></name><name><surname>Reed</surname><given-names>W.</given-names></name><name><surname>Bromberg</surname><given-names>P.A.</given-names></name><name><surname>Samet</surname><given-names>J.M.</given-names></name></person-group><article-title>Diesel exhaust particulate-induced activation of Stat3 requires activities of EGFR and Src in airway epithelial cells</article-title><source>Am. J. Physiol. Lung Cell. Mol. Physiol.</source><year>2007</year><volume>292</volume><fpage>L422</fpage><lpage>L429</lpage><pub-id pub-id-type="doi">10.1152/ajplung.00204.2006</pub-id><?supplied-pmid 17028263?><pub-id pub-id-type="pmid">17028263</pub-id></element-citation></ref><ref id="B9-pharmaceuticals-14-00002"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Ping</surname><given-names>F.</given-names></name><name><surname>Zheng</surname><given-names>X.</given-names></name></person-group><article-title>[Effect of PM2.5 on oxidative stress-JAK/STAT signaling pathway of human bronchial epithelial cells]</article-title><source>Wei Sheng Yan Jiu</source><year>2015</year><volume>44</volume><fpage>451</fpage><lpage>455</lpage><?supplied-pmid 26137628?><pub-id pub-id-type="pmid">26137628</pub-id></element-citation></ref><ref id="B10-pharmaceuticals-14-00002"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aziz</surname><given-names>Z.A.A.</given-names></name><name><surname>Ahmad</surname><given-names>A.</given-names></name><name><surname>Mohd-Setapar</surname><given-names>S.H.</given-names></name><name><surname>Karakucuk</surname><given-names>A.</given-names></name><name><surname>Azim</surname><given-names>M.M.</given-names></name><name><surname>Lokhat</surname><given-names>D.</given-names></name><name><surname>Rafatullah</surname><given-names>M.</given-names></name><name><surname>Ganash</surname><given-names>M.</given-names></name><name><surname>Kamal</surname><given-names>M.A.</given-names></name><name><surname>Ashraf</surname><given-names>G.M.</given-names></name></person-group><article-title>Essential Oils: Extraction Techniques, Pharmaceutical And Therapeutic Potential&#x02014;A Review</article-title><source>Curr. Drug Metab.</source><year>2018</year><volume>19</volume><fpage>1100</fpage><lpage>1110</lpage><pub-id pub-id-type="doi">10.2174/1389200219666180723144850</pub-id><pub-id pub-id-type="pmid">30039757</pub-id></element-citation></ref><ref id="B11-pharmaceuticals-14-00002"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anwar</surname><given-names>F.</given-names></name><name><surname>Abbas</surname><given-names>A.</given-names></name><name><surname>Mehmood</surname><given-names>T.</given-names></name><name><surname>Gilani</surname><given-names>A.-H.</given-names></name><name><surname>Rehman</surname><given-names>N.</given-names></name></person-group><article-title>Mentha: A genus rich in vital nutra-pharmaceuticals&#x02014;A review</article-title><source>Phytotherapy Res.</source><year>2019</year><volume>33</volume><fpage>2548</fpage><lpage>2570</lpage><pub-id pub-id-type="doi">10.1002/ptr.6423</pub-id></element-citation></ref><ref id="B12-pharmaceuticals-14-00002"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>P.</given-names></name><name><surname>Pandey</surname><given-names>A.K.</given-names></name></person-group><article-title>Prospective of Essential Oils of the Genus Mentha as Biopesticides: A Review</article-title><source>Front. Plant Sci.</source><year>2018</year><volume>9</volume><fpage>1295</fpage><pub-id pub-id-type="doi">10.3389/fpls.2018.01295</pub-id><?supplied-pmid 30250476?><pub-id pub-id-type="pmid">30250476</pub-id></element-citation></ref><ref id="B13-pharmaceuticals-14-00002"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>S.</given-names></name><name><surname>Rasal</surname><given-names>V.P.</given-names></name><name><surname>Patil</surname><given-names>P.A.</given-names></name><name><surname>Joshi</surname><given-names>R.K.</given-names></name></person-group><article-title>Mentha arvensis essential oil suppressed airway changes induced by histamine and ovalbumin in experimental animals</article-title><source>Nat. Prod. Res.</source><year>2018</year><volume>32</volume><fpage>468</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1080/14786419.2017.1311891</pub-id><?supplied-pmid 28385073?><pub-id pub-id-type="pmid">28385073</pub-id></element-citation></ref><ref id="B14-pharmaceuticals-14-00002"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaradat</surname><given-names>N.</given-names></name><name><surname>Al Zabadi</surname><given-names>H.</given-names></name><name><surname>Rahhal</surname><given-names>B.</given-names></name><name><surname>Hussein</surname><given-names>A.M.A.</given-names></name><name><surname>Mahmoud</surname><given-names>J.S.</given-names></name><name><surname>Mansour</surname><given-names>B.</given-names></name><name><surname>Khasati</surname><given-names>A.I.</given-names></name><name><surname>Issa</surname><given-names>A.</given-names></name></person-group><article-title>The effect of inhalation of Citrus sinensis flowers and Mentha spicata leave essential oils on lung function and exercise performance: A quasi-experimental uncontrolled before-and-after study</article-title><source>J. Int. Soc. Sports Nutr.</source><year>2016</year><volume>13</volume><fpage>36</fpage><pub-id pub-id-type="doi">10.1186/s12970-016-0146-7</pub-id><?supplied-pmid 27688737?><pub-id pub-id-type="pmid">27688737</pub-id></element-citation></ref><ref id="B15-pharmaceuticals-14-00002"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whiley</surname><given-names>H.</given-names></name><name><surname>Gaskin</surname><given-names>S.</given-names></name><name><surname>Schroder</surname><given-names>T.</given-names></name><name><surname>Ross</surname><given-names>K.E.</given-names></name></person-group><article-title>Antifungal properties of essential oils for improvement of indoor air quality: A review</article-title><source>Rev. Environ. Heal.</source><year>2018</year><volume>33</volume><fpage>63</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1515/reveh-2017-0023</pub-id><?supplied-pmid 29077554?><pub-id pub-id-type="pmid">29077554</pub-id></element-citation></ref><ref id="B16-pharmaceuticals-14-00002"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chambers</surname><given-names>L.</given-names></name><name><surname>Finch</surname><given-names>J.</given-names></name><name><surname>Edwards</surname><given-names>K.</given-names></name><name><surname>Jeanjean</surname><given-names>A.</given-names></name><name><surname>Leigh</surname><given-names>R.</given-names></name><name><surname>Gonem</surname><given-names>S.</given-names></name></person-group><article-title>Effects of personal air pollution exposure on asthma symptoms, lung function and airway inflammation</article-title><source>Clin. Exp. Allergy</source><year>2018</year><volume>48</volume><fpage>798</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.1111/cea.13130</pub-id><pub-id pub-id-type="pmid">29526044</pub-id></element-citation></ref><ref id="B17-pharmaceuticals-14-00002"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camelo</surname><given-names>A.</given-names></name><name><surname>Dunmore</surname><given-names>R.</given-names></name><name><surname>Sleeman</surname><given-names>M.A.</given-names></name><name><surname>Clarke</surname><given-names>D.L.</given-names></name></person-group><article-title>The epithelium in idiopathic pulmonary fibrosis: Breaking the barrier</article-title><source>Front. Pharmacol.</source><year>2014</year><volume>4</volume><fpage>173</fpage><pub-id pub-id-type="doi">10.3389/fphar.2013.00173</pub-id><pub-id pub-id-type="pmid">24454287</pub-id></element-citation></ref><ref id="B18-pharmaceuticals-14-00002"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z.</given-names></name><name><surname>Ning</surname><given-names>W.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Hua</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>D.</given-names></name><name><surname>Zheng</surname><given-names>M.</given-names></name><name><surname>Deng</surname><given-names>X.</given-names></name></person-group><article-title>Effects of chronic PM2.5 exposure on pulmonary epithelia: Transcriptome analysis of mRNA-exosomal miRNA interactions</article-title><source>Toxicol. Lett.</source><year>2019</year><volume>316</volume><fpage>49</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.toxlet.2019.09.010</pub-id><pub-id pub-id-type="pmid">31520698</pub-id></element-citation></ref><ref id="B19-pharmaceuticals-14-00002"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>R.K.</given-names></name><name><surname>Shadie</surname><given-names>A.M.</given-names></name><name><surname>Bucknall</surname><given-names>M.</given-names></name><name><surname>Rutlidge</surname><given-names>H.</given-names></name><name><surname>Garthwaite</surname><given-names>L.</given-names></name><name><surname>Herbert</surname><given-names>C.</given-names></name><name><surname>Halliburton</surname><given-names>B.</given-names></name><name><surname>Parsons</surname><given-names>K.</given-names></name><name><surname>Wark</surname><given-names>P.A.</given-names></name></person-group><article-title>Differential injurious effects of ambient and traffic-derived particulate matter on airway epithelial cells</article-title><source>Respirology</source><year>2015</year><volume>20</volume><fpage>73</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1111/resp.12381</pub-id><pub-id pub-id-type="pmid">25219656</pub-id></element-citation></ref><ref id="B20-pharmaceuticals-14-00002"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maglione</surname><given-names>G.A.</given-names></name><name><surname>Kurtz</surname><given-names>M.L.</given-names></name><name><surname>Orona</surname><given-names>N.S.</given-names></name><name><surname>Astort</surname><given-names>F.</given-names></name><name><surname>Busso</surname><given-names>I.T.</given-names></name><name><surname>Mandalunis</surname><given-names>P.M.</given-names></name><name><surname>Berra</surname><given-names>A.</given-names></name><name><surname>Tasat</surname><given-names>D.R.</given-names></name></person-group><article-title>Chronic exposure to urban air pollution from Buenos Aires: The ocular mucosa as an early biomarker</article-title><source>Environ. Sci. Pollut. Res.</source><year>2019</year><volume>26</volume><fpage>27444</fpage><lpage>27456</lpage><pub-id pub-id-type="doi">10.1007/s11356-019-05966-6</pub-id></element-citation></ref><ref id="B21-pharmaceuticals-14-00002"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darnell</surname><given-names>J.E.</given-names></name><name><surname>Kerr</surname><given-names>I.M.</given-names></name><name><surname>Stark</surname><given-names>G.R.</given-names></name></person-group><article-title>Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins</article-title><source>Science</source><year>1994</year><volume>264</volume><fpage>1415</fpage><lpage>1421</lpage><pub-id pub-id-type="doi">10.1126/science.8197455</pub-id><?supplied-pmid 8197455?><pub-id pub-id-type="pmid">8197455</pub-id></element-citation></ref><ref id="B22-pharmaceuticals-14-00002"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Asweto</surname><given-names>C.</given-names></name><name><surname>Feng</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Duan</surname><given-names>F.</given-names></name><name><surname>Duan</surname><given-names>J.</given-names></name><name><surname>Sun</surname><given-names>Z.</given-names></name></person-group><article-title>Fine particulate matter induces vascular endothelial activation via IL-6 dependent JAK1/STAT3 signaling pathway</article-title><source>Toxicol. Res.</source><year>2016</year><volume>5</volume><fpage>946</fpage><lpage>953</lpage><pub-id pub-id-type="doi">10.1039/C5TX00351B</pub-id><?supplied-pmid 30090403?><pub-id pub-id-type="pmid">30090403</pub-id></element-citation></ref><ref id="B23-pharmaceuticals-14-00002"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>D.E.</given-names></name><name><surname>O&#x02019;Keefe</surname><given-names>R.A.</given-names></name><name><surname>Grandis</surname><given-names>J.R.</given-names></name></person-group><article-title>Targeting the IL-6/JAK/STAT3 signalling axis in cancer</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2018</year><volume>15</volume><fpage>234</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2018.8</pub-id><?supplied-pmid 29405201?><pub-id pub-id-type="pmid">29405201</pub-id></element-citation></ref><ref id="B24-pharmaceuticals-14-00002"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ta&#x0015f;</surname><given-names>I.</given-names></name><name><surname>Zhou</surname><given-names>R.</given-names></name><name><surname>Park</surname><given-names>S.-Y.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Gamage</surname><given-names>C.D.</given-names></name><name><surname>Son</surname><given-names>Y.-J.</given-names></name><name><surname>Paik</surname><given-names>M.-J.</given-names></name><name><surname>Kim</surname><given-names>H.</given-names></name></person-group><article-title>Inflammatory and tumorigenic effects of environmental pollutants found in particulate matter on lung epithelial cells</article-title><source>Toxicol. In Vitro</source><year>2019</year><volume>59</volume><fpage>300</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1016/j.tiv.2019.05.022</pub-id><pub-id pub-id-type="pmid">31154059</pub-id></element-citation></ref><ref id="B25-pharmaceuticals-14-00002"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Ji</surname><given-names>N.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Sun</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>F.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Huang</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name></person-group><article-title>Fine Particulate Matter (PM2.5) Promoted the Invasion of Lung Cancer Cells via an ARNT2/PP2A/STAT3/MMP2 Pathway</article-title><source>J. Biomed. Nanotechnol.</source><year>2018</year><volume>14</volume><fpage>2172</fpage><lpage>2184</lpage><pub-id pub-id-type="doi">10.1166/jbn.2018.2645</pub-id><pub-id pub-id-type="pmid">30305224</pub-id></element-citation></ref><ref id="B26-pharmaceuticals-14-00002"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reyes-Z&#x000e1;rate</surname><given-names>E.</given-names></name><name><surname>S&#x000e1;nchez-P&#x000e9;rez</surname><given-names>Y.</given-names></name><name><surname>Guti&#x000e9;rrez-Ruiz</surname><given-names>M.</given-names></name><name><surname>Chirino</surname><given-names>Y.I.</given-names></name><name><surname>Osornio-Vargas</surname><given-names>A.R.</given-names></name><name><surname>Morales-B&#x000e1;rcenas</surname><given-names>R.</given-names></name><name><surname>Souza-Arroyo</surname><given-names>V.</given-names></name><name><surname>Garc&#x000ed;a-Cuellar</surname><given-names>C.M.</given-names></name></person-group><article-title>Atmospheric particulate matter (PM10) exposure-induced cell cycle arrest and apoptosis evasion through STAT3 activation via PKC&#x003b6; and Src kinases in lung cells</article-title><source>Environ. Pollut.</source><year>2016</year><volume>214</volume><fpage>646</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1016/j.envpol.2016.04.072</pub-id><pub-id pub-id-type="pmid">27131825</pub-id></element-citation></ref><ref id="B27-pharmaceuticals-14-00002"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>T.C.</given-names></name><name><surname>Pellegrini</surname><given-names>S.</given-names></name></person-group><article-title>The Janus kinase family of protein tyrosine kinases and their role in signaling</article-title><source>Cell. Mol. Life Sci.</source><year>1999</year><volume>55</volume><fpage>1523</fpage><lpage>1534</lpage><pub-id pub-id-type="doi">10.1007/s000180050392</pub-id><pub-id pub-id-type="pmid">10526570</pub-id></element-citation></ref><ref id="B28-pharmaceuticals-14-00002"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wegmann</surname><given-names>M.</given-names></name></person-group><article-title>Th2 cells as targets for therapeutic intervention in allergic bronchial asthma</article-title><source>Expert Rev. Mol. Diagn.</source><year>2009</year><volume>9</volume><fpage>85</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1586/14737159.9.1.85</pub-id><pub-id pub-id-type="pmid">19099351</pub-id></element-citation></ref><ref id="B29-pharmaceuticals-14-00002"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simeone-Penney</surname><given-names>M.C.</given-names></name><name><surname>Severgnini</surname><given-names>M.</given-names></name><name><surname>Tu</surname><given-names>P.</given-names></name><name><surname>Homer</surname><given-names>R.J.</given-names></name><name><surname>Mariani</surname><given-names>T.J.</given-names></name><name><surname>Cohn</surname><given-names>L.</given-names></name><name><surname>Simon</surname><given-names>A.R.</given-names></name></person-group><article-title>Airway Epithelial STAT3 Is Required for Allergic Inflammation in a Murine Model of Asthma</article-title><source>J. Immunol.</source><year>2007</year><volume>178</volume><fpage>6191</fpage><lpage>6199</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.178.10.6191</pub-id><pub-id pub-id-type="pmid">17475846</pub-id></element-citation></ref><ref id="B30-pharmaceuticals-14-00002"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzarella</surname><given-names>G.</given-names></name><name><surname>Esposito</surname><given-names>V.</given-names></name><name><surname>Bianco</surname><given-names>A.</given-names></name><name><surname>Ferraraccio</surname><given-names>F.</given-names></name><name><surname>Prati</surname><given-names>M.</given-names></name><name><surname>Lucariello</surname><given-names>A.</given-names></name><name><surname>Manente</surname><given-names>L.</given-names></name><name><surname>Mezzogiorno</surname><given-names>A.</given-names></name><name><surname>De Luca</surname><given-names>A.</given-names></name></person-group><article-title>Inflammatory effects on human lung epithelial cells after exposure to diesel exhaust micron sub particles (PM1.0) and pollen allergens</article-title><source>Environ. Pollut.</source><year>2012</year><volume>161</volume><fpage>64</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.envpol.2011.09.046</pub-id><pub-id pub-id-type="pmid">22230069</pub-id></element-citation></ref><ref id="B31-pharmaceuticals-14-00002"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hillmer</surname><given-names>E.J.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>H.S.</given-names></name><name><surname>Watowich</surname><given-names>S.S.</given-names></name></person-group><article-title>STAT3 signaling in immunity</article-title><source>Cytokine Growth Factor Rev.</source><year>2016</year><volume>31</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2016.05.001</pub-id><?supplied-pmid 27185365?><pub-id pub-id-type="pmid">27185365</pub-id></element-citation></ref><ref id="B32-pharmaceuticals-14-00002"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Lewis</surname><given-names>D.F.</given-names></name><name><surname>Gu</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Groome</surname><given-names>L.J.</given-names></name></person-group><article-title>Elevated Maternal Soluble Gp130 and IL-6 Levels and Reduced Gp130 and SOCS-3 Expressions in Women Complicated With Preeclampsia</article-title><source>Hypertension</source><year>2011</year><volume>57</volume><fpage>336</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.110.163360</pub-id><?supplied-pmid 21173340?><pub-id pub-id-type="pmid">21173340</pub-id></element-citation></ref><ref id="B33-pharmaceuticals-14-00002"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dagouassat</surname><given-names>M.</given-names></name><name><surname>Lanone</surname><given-names>S.</given-names></name><name><surname>Boczkowski</surname><given-names>J.</given-names></name></person-group><article-title>Interaction of matrix metalloproteinases with pulmonary pollutants</article-title><source>Eur. Respir. J.</source><year>2012</year><volume>39</volume><fpage>1021</fpage><lpage>1032</lpage><pub-id pub-id-type="doi">10.1183/09031936.00195811</pub-id><?supplied-pmid 22241746?><pub-id pub-id-type="pmid">22241746</pub-id></element-citation></ref><ref id="B34-pharmaceuticals-14-00002"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>G.</given-names></name><name><surname>Karin</surname><given-names>M.</given-names></name></person-group><article-title>NF-&#x003ba;B and STAT3&#x02013;key players in liver inflammation and cancer</article-title><source>Cell Res.</source><year>2011</year><volume>21</volume><fpage>159</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1038/cr.2010.183</pub-id><pub-id pub-id-type="pmid">21187858</pub-id></element-citation></ref><ref id="B35-pharmaceuticals-14-00002"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H.</given-names></name><name><surname>Herrmann</surname><given-names>A.</given-names></name><name><surname>Deng</surname><given-names>J.-H.</given-names></name><name><surname>Kujawski</surname><given-names>M.</given-names></name><name><surname>Niu</surname><given-names>G.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Forman</surname><given-names>S.</given-names></name><name><surname>Jove</surname><given-names>R.</given-names></name><name><surname>Pardoll</surname><given-names>D.M.</given-names></name><name><surname>Yu</surname><given-names>H.</given-names></name></person-group><article-title>Persistently Activated Stat3 Maintains Constitutive NF-&#x003ba;B Activity in Tumors</article-title><source>Cancer Cell</source><year>2009</year><volume>15</volume><fpage>283</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2009.02.015</pub-id><pub-id pub-id-type="pmid">19345327</pub-id></element-citation></ref><ref id="B36-pharmaceuticals-14-00002"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>E.</given-names></name><name><surname>Bail</surname><given-names>S.</given-names></name><name><surname>Buchbauer</surname><given-names>G.</given-names></name><name><surname>Stoilova</surname><given-names>I.</given-names></name><name><surname>Atanasova</surname><given-names>T.</given-names></name><name><surname>Stoyanova</surname><given-names>A.</given-names></name><name><surname>Krastanov</surname><given-names>A.</given-names></name><name><surname>Jirovetz</surname><given-names>L.</given-names></name></person-group><article-title>Chemical Composition, Olfactory Evaluation and Antioxidant Effects of Essential Oil from Mentha x piperita</article-title><source>Nat. Prod. Commun.</source><year>2009</year><volume>4</volume><fpage>1107</fpage><lpage>1112</lpage><pub-id pub-id-type="doi">10.1177/1934578X0900400819</pub-id><pub-id pub-id-type="pmid">19768994</pub-id></element-citation></ref><ref id="B37-pharmaceuticals-14-00002"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mostafavi</surname><given-names>S.</given-names></name><name><surname>Ray</surname><given-names>D.</given-names></name><name><surname>Warde-Farley</surname><given-names>D.</given-names></name><name><surname>Grouios</surname><given-names>C.</given-names></name><name><surname>Morris</surname><given-names>Q.D.</given-names></name></person-group><article-title>GeneMANIA: A real-time multiple association network integration algorithm for predicting gene function</article-title><source>Genome Biol.</source><year>2008</year><volume>9</volume><issue>Suppl. 1</issue><fpage>S4</fpage><pub-id pub-id-type="doi">10.1186/gb-2008-9-s1-s4</pub-id></element-citation></ref><ref id="B38-pharmaceuticals-14-00002"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Assenov</surname><given-names>Y.</given-names></name><name><surname>Ram&#x000ed;rez</surname><given-names>F.</given-names></name><name><surname>Schelhorn</surname><given-names>S.-E.</given-names></name><name><surname>Lengauer</surname><given-names>T.</given-names></name><name><surname>Albrecht</surname><given-names>M.</given-names></name></person-group><article-title>Computing topological parameters of biological networks</article-title><source>Bioinformatics</source><year>2008</year><volume>24</volume><fpage>282</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btm554</pub-id><pub-id pub-id-type="pmid">18006545</pub-id></element-citation></ref><ref id="B39-pharmaceuticals-14-00002"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denkers</surname><given-names>N.D.</given-names></name><name><surname>Seelig</surname><given-names>D.M.</given-names></name><name><surname>Telling</surname><given-names>G.C.</given-names></name><name><surname>Hoover</surname><given-names>E.A.</given-names></name></person-group><article-title>Aerosol and nasal transmission of chronic wasting disease in cervidized mice</article-title><source>J. Gen. Virol.</source><year>2010</year><volume>91</volume><fpage>1651</fpage><lpage>1658</lpage><pub-id pub-id-type="doi">10.1099/vir.0.017335-0</pub-id><pub-id pub-id-type="pmid">20164261</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="pharmaceuticals-14-00002-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>The structures of menthol and menthone, major components of <italic>Mentha</italic> essential oil (<bold>A</bold>). Protein&#x02013;protein interaction network of <italic>Mentha</italic> essential oils (MEO) (<bold>B</bold>). The nodes and edges indicate the proteins and their relationships. Module extracted by Gene ontology enrichment analysis (<bold>C</bold>). The black nodes present seed nodes and the gray ones are nodes that interact with the seed nodes. Purple, Co-expression; Blue, Co-localization; Pink, Physical interactions; Yellow, shared protein domains; Orange, Predicted; Green, Genetic interactions; Sky, pathway.</p></caption><graphic xlink:href="pharmaceuticals-14-00002-g001"/></fig><fig id="pharmaceuticals-14-00002-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Pathway analysis performed on the &#x0201c;Enrichr&#x0201d; platform. The enriched pathway terms are displayed in a bar graph (<bold>A</bold>). The length of the bar and the brightness of its color represent the significance of the specific pathway. Clustergram of pathways of MEO (<bold>B</bold>). Those clusters are ranked by <italic>p</italic> value. The colors of the boxes represent each cluster.</p></caption><graphic xlink:href="pharmaceuticals-14-00002-g002"/></fig><fig id="pharmaceuticals-14-00002-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Histological changes of lung tissues stained by Hematoxylin and Eosin (<bold>A</bold>), Masson&#x02019;s trichrome (<bold>B</bold>) and Periodic acid&#x02013;Schiff (PAS) (<bold>C</bold>) in ovalbumin (OVA) and PM<sub>10</sub>-exposed mice. Thickness of respiratory epithelium (<bold>D</bold>), collagen deposition % of area (<bold>E</bold>) and goblet cell number per area (<bold>F</bold>) were shown as relative quantified values. The slides of each mice (<italic>n</italic> = 7) were evaluated by randomly selecting 3 photographs and a total 21 images were quantified using Image J computerized densitometry system. Results are presented as mean &#x000b1; standard error of the mean. <sup>###</sup>
<italic>p</italic> &#x0003c; 0.001 vs. CTR group; * <italic>p</italic> &#x0003c; 0.05, ** <italic>p</italic> &#x0003c; 0.01 and *** <italic>p</italic> &#x0003c; 0.001 vs. PM<sub>10</sub> group.</p></caption><graphic xlink:href="pharmaceuticals-14-00002-g003"/></fig><fig id="pharmaceuticals-14-00002-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>The mRNA expressions of IL-6 (<bold>A</bold>), inflammatory cytokines including TNF-&#x003b1;, IL-1&#x003b2;, IL-5 and IL-8 (<bold>B</bold>), Th2-specific cytokines including IL-4 and IL-13 (<bold>C</bold>), and MMP-2 and MMP-9 (<bold>D</bold>) in PM<sub>10</sub>-exposed A549 lung epithelial cells. The experiments were carried out in triplicate measurements. Results are presented as mean &#x000b1; standard error of the mean. <sup>###</sup>
<italic>p</italic> &#x0003c; 0.001 vs. non-treated cells; * <italic>p</italic> &#x0003c; 0.05, and *** <italic>p</italic> &#x0003c; 0.001 vs. PM<sub>10</sub>-treated cells.</p></caption><graphic xlink:href="pharmaceuticals-14-00002-g004"/></fig><fig id="pharmaceuticals-14-00002-f005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>The protein expressions of JAK1 and JAK2 in PM<sub>10</sub>-exposed A549 lung epithelial cells (<bold>A</bold>). The protein expression of STAT3 in PM<sub>10</sub>-exposed A549 lung epithelial cells (<bold>B</bold>). The experiments were carried out in triplicate measurements. Results are presented as mean &#x000b1; standard error of the mean. <sup>###</sup>
<italic>p</italic> &#x0003c; 0.001 vs. non-treated cells; * <italic>p</italic> &#x0003c; 0.05, ** <italic>p</italic> &#x0003c; 0.01 and *** <italic>p</italic> &#x0003c; 0.001 vs. PM<sub>10</sub>-treated cells.</p></caption><graphic xlink:href="pharmaceuticals-14-00002-g005"/></fig><fig id="pharmaceuticals-14-00002-f006" orientation="portrait" position="float"><label>Figure 6</label><caption><p>The protein expressions of nuclear NF-&#x003ba;B, cytosolic NF-&#x003ba;B, and I&#x003ba;B-&#x003b1; in PM<sub>10</sub>-exposed A549 lung epithelial cells. The experiments were carried out in triplicate measurements. Results are presented as mean &#x000b1; standard error of the mean. <sup>###</sup>
<italic>p</italic> &#x0003c; 0.001 vs. non-treated cells; * <italic>p</italic> &#x0003c; 0.05, ** <italic>p</italic> &#x0003c; 0.01 and *** <italic>p</italic> &#x0003c; 0.001 vs. PM<sub>10</sub>-treated cells.</p></caption><graphic xlink:href="pharmaceuticals-14-00002-g006"/></fig><fig id="pharmaceuticals-14-00002-f007" orientation="portrait" position="float"><label>Figure 7</label><caption><p>Schematic diagram of potential action of MEO on asthma under exposure of PM via inhibition of IL-6/JAK2/STAT3 pathway.</p></caption><graphic xlink:href="pharmaceuticals-14-00002-g007"/></fig><table-wrap id="pharmaceuticals-14-00002-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceuticals-14-00002-t001_Table 1</object-id><label>Table 1</label><caption><p>Biological processes related to targets of MEO. Modules were assigned to biological processes using KEGG pathway 2019 human.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Module</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">KEGG Pathway 2019 Human</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic> Value</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">GO Biological Process 2018</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic> Value</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">M1</td><td align="center" valign="middle" rowspan="1" colspan="1">Mineral absorption</td><td align="center" valign="middle" rowspan="1" colspan="1">6.5 &#x000d7; 10<sup>&#x02212;4</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">calcium ion transport (GO:0006816)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.5 &#x000d7; 10<sup>&#x02212;22</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">M2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cytokine&#x02013;cytokine receptor interaction</td><td align="center" valign="middle" rowspan="1" colspan="1">2.8 &#x000d7; 10<sup>&#x02212;16</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">cellular response to cytokine stimulus (GO:0071345)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5 &#x000d7; 10<sup>&#x02212;</sup><sup>14</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">M3</td><td align="center" valign="middle" rowspan="1" colspan="1">Retinol metabolism</td><td align="center" valign="middle" rowspan="1" colspan="1">1.1 &#x000d7; 10<sup>&#x02212;4</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">coumarin metabolic process (GO:0009804)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5 &#x000d7; 10<sup>&#x02212;3</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">M4</td><td align="center" valign="middle" rowspan="1" colspan="1">Other glycan degradation</td><td align="center" valign="middle" rowspan="1" colspan="1">3.6 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">positive regulation of action potential (GO:0045760)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.2 &#x000d7; 10<sup>&#x02212;3</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">M5</td><td align="center" valign="middle" rowspan="1" colspan="1">Legionellosis</td><td align="center" valign="middle" rowspan="1" colspan="1">1.1 &#x000d7; 10<sup>&#x02212;6</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">response to organic cyclic compound (GO:0014070)</td><td align="center" valign="middle" rowspan="1" colspan="1">3.2 &#x000d7; 10<sup>&#x02212;4</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">M6</td><td align="center" valign="middle" rowspan="1" colspan="1">Th1 and Th2 cell differentiation</td><td align="center" valign="middle" rowspan="1" colspan="1">4.3 &#x000d7; 10<sup>&#x02212;4</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">positive regulation of T-helper 17 type immune response (GO:2000318)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.1 &#x000d7; 10<sup>&#x02212;3</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neuroactive ligand-receptor interaction</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.4 &#x000d7; 10<sup>&#x02212;5</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">positive regulation of cytosolic calcium ion concentration (GO:0007204)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.4 &#x000d7; 10<sup>&#x02212;6</sup></td></tr></tbody></table></table-wrap><table-wrap id="pharmaceuticals-14-00002-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceuticals-14-00002-t002_Table 2</object-id><label>Table 2</label><caption><p>Cluster of the enriched pathway of MEO.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cluster No.</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">KEGG Pathway 2019 Human</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic> Value</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cluster 1</td><td align="center" valign="middle" rowspan="1" colspan="1">Cytokine&#x02013;cytokine receptor interaction</td><td align="center" valign="middle" rowspan="1" colspan="1">2.779 &#x000d7; 10<sup>&#x02212;16</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cluster 2</td><td align="center" valign="middle" rowspan="1" colspan="1">JAK-STAT signaling pathway</td><td align="center" valign="middle" rowspan="1" colspan="1">6.906 &#x000d7; 10<sup>&#x02212;</sup><sup>16</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cluster 3</td><td align="center" valign="middle" rowspan="1" colspan="1">Inflammatory bowel disease (IBD)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.932 &#x000d7; 10<sup>&#x02212;</sup><sup>13</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cluster 4</td><td align="center" valign="middle" rowspan="1" colspan="1">Intestinal immune network for IgA production</td><td align="center" valign="middle" rowspan="1" colspan="1">1.604 &#x000d7; 10<sup>&#x02212;</sup><sup>11</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cluster 5</td><td align="center" valign="middle" rowspan="1" colspan="1">Autoimmune thyroid disease</td><td align="center" valign="middle" rowspan="1" colspan="1">2.685 &#x000d7; 10<sup>&#x02212;</sup><sup>11</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cluster 6</td><td align="center" valign="middle" rowspan="1" colspan="1">IL-17 signaling pathway</td><td align="center" valign="middle" rowspan="1" colspan="1">4.823 &#x000d7; 10<sup>&#x02212;</sup><sup>10</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cluster 7</td><td align="center" valign="middle" rowspan="1" colspan="1">Hematopoietic cell lineage</td><td align="center" valign="middle" rowspan="1" colspan="1">5.976 &#x000d7; 10<sup>&#x02212;</sup><sup>10</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cluster 8</td><td align="center" valign="middle" rowspan="1" colspan="1">T cell receptor signaling pathway</td><td align="center" valign="middle" rowspan="1" colspan="1">7.339 &#x000d7; 10<sup>&#x02212;</sup><sup>10</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cluster 9</td><td align="center" valign="middle" rowspan="1" colspan="1">Asthma</td><td align="center" valign="middle" rowspan="1" colspan="1">9.848 &#x000d7; 10<sup>&#x02212;</sup><sup>10</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cluster 10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Allograft rejection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.307 &#x000d7; 10<sup>&#x02212;</sup><sup>9</sup></td></tr></tbody></table></table-wrap></floats-group></article>